487 related articles for article (PubMed ID: 3488858)
1. Complement mediated inhibition of immune precipitation and solubilization generate different concentrations of complement anaphylatoxins (C4a, C3a, C5a).
Schifferli JA; Steiger G; Paccaud JP
Clin Exp Immunol; 1986 May; 64(2):407-14. PubMed ID: 3488858
[TBL] [Abstract][Full Text] [Related]
2. Generation of human C3a, C4a, and C5a anaphylatoxins by protein A of Staphylococcus aureus and immobilized protein A reagents used in serotherapy of cancer.
Langone JJ; Das C; Bennett D; Terman DS
J Immunol; 1984 Aug; 133(2):1057-63. PubMed ID: 6610702
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of immune precipitation by complement.
Hong K; Takata Y; Sayama K; Kozono H; Takeda J; Nakano Y; Kinoshita T; Inoue K
J Immunol; 1984 Sep; 133(3):1464-70. PubMed ID: 6747294
[TBL] [Abstract][Full Text] [Related]
4. [Atopic dermatitis. II. The status of complement proteins and the pathogenetic role of anaphylatoxins C4a, C3a and C5a].
Sergeev IuV; Reznikov IuP; Lobanova EV; Pimenova NS
Vestn Dermatol Venerol; 1989; (4):4-7. PubMed ID: 2788339
[TBL] [Abstract][Full Text] [Related]
5. Formation of soluble immune complexes by complement in sera of patients with various hypocomplementemic states. Difference between inhibition of immune precipitation and solubilization.
Schifferli JA; Steiger G; Hauptmann G; Spaeth PJ; Sjöholm AG
J Clin Invest; 1985 Dec; 76(6):2127-33. PubMed ID: 2934406
[TBL] [Abstract][Full Text] [Related]
6. Anaphylatoxin levels in human aqueous humor.
Mondino BJ; Sumner H
Invest Ophthalmol Vis Sci; 1986 Aug; 27(8):1288-92. PubMed ID: 3488296
[TBL] [Abstract][Full Text] [Related]
7. Relative inefficiency of terminal complement activation.
Bhakdi S; Fassbender W; Hugo F; Carreno MP; Berstecher C; Malasit P; Kazatchkine MD
J Immunol; 1988 Nov; 141(9):3117-22. PubMed ID: 3262681
[TBL] [Abstract][Full Text] [Related]
8. Difference in the biological properties of the two forms of the fourth component of human complement (C4).
Schifferli JA; Steiger G; Paccaud JP; Sjöholm AG; Hauptmann G
Clin Exp Immunol; 1986 Feb; 63(2):473-7. PubMed ID: 3486068
[TBL] [Abstract][Full Text] [Related]
9. Complement activation in patients with primary antiphospholipid syndrome.
Oku K; Atsumi T; Bohgaki M; Amengual O; Kataoka H; Horita T; Yasuda S; Koike T
Ann Rheum Dis; 2009 Jun; 68(6):1030-5. PubMed ID: 18625630
[TBL] [Abstract][Full Text] [Related]
10. Anaphylatoxin levels in human vitreous humor.
Mondino BJ; Sidikaro Y; Sumner H
Invest Ophthalmol Vis Sci; 1988 Jul; 29(7):1195-8. PubMed ID: 3262096
[TBL] [Abstract][Full Text] [Related]
11. The extracellular neutral cysteine proteinase of Entamoeba histolytica degrades anaphylatoxins C3a and C5a.
Reed SL; Ember JA; Herdman DS; DiScipio RG; Hugli TE; Gigli I
J Immunol; 1995 Jul; 155(1):266-74. PubMed ID: 7602103
[TBL] [Abstract][Full Text] [Related]
12. Polyacrylonitrile complement activation attenuated by simultaneous ultrafiltration and adsorption.
Röckel A; Hertel J; Perschel WT; Walb D; Fiegel P; Panitz N; Abdelhamid S
Nephrol Dial Transplant; 1987; 2(4):251-3. PubMed ID: 3118267
[TBL] [Abstract][Full Text] [Related]
13. C5a: a mediator of chemotaxis and cellular release reactions.
Gerard C; Hugli TE
Kroc Found Ser; 1981; 14():147-60. PubMed ID: 6975805
[No Abstract] [Full Text] [Related]
14. Complement and dengue haemorrhagic fever/shock syndrome.
Malasit P
Southeast Asian J Trop Med Public Health; 1987 Sep; 18(3):316-20. PubMed ID: 3501613
[TBL] [Abstract][Full Text] [Related]
15. Complement activation and anaphylatoxin (C3a and C5a) formation in preeclampsia and by amniotic fluid.
Haeger M; Bengtson A; Karlsson K; Heideman M
Obstet Gynecol; 1989 Apr; 73(4):551-6. PubMed ID: 2784554
[TBL] [Abstract][Full Text] [Related]
16. Isolation of three separate anaphylatoxins from complement-activated human serum.
Hugli TE; Gerard C; Kawahara M; Scheetz ME; Barton R; Briggs S; Koppel G; Russell S
Mol Cell Biochem; 1981 Dec; 41():59-66. PubMed ID: 6977086
[TBL] [Abstract][Full Text] [Related]
17. Plasma lactoferrin reflects granulocyte activation via complement in burn patients.
Wolach B; Coates TD; Hugli TE; Baehner RL; Boxer LA
J Lab Clin Med; 1984 Feb; 103(2):284-93. PubMed ID: 6607301
[TBL] [Abstract][Full Text] [Related]
18. Purification and functional assessment of C3a, C4a and C5a of the common carp (Cyprinus carpio) complement.
Kato Y; Nakao M; Shimizu M; Wariishi H; Yano T
Dev Comp Immunol; 2004 Jul; 28(9):901-10. PubMed ID: 15183031
[TBL] [Abstract][Full Text] [Related]
19. Control of immune complexes by the classical pathway.
Whaley K; Ahmed AE
Behring Inst Mitt; 1989 Jul; (84):111-20. PubMed ID: 2529842
[TBL] [Abstract][Full Text] [Related]
20. The activation of C3 and C4 in human serum by immune complexes containing mouse monoclonal antibodies of different isotype and affinity: effects on solubilisation.
Stewart WW; Johnson A; Steward MW; Whaley K; Kerr MA
Mol Immunol; 1988 Dec; 25(12):1355-61. PubMed ID: 3266294
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
